DK0526348T3 - Indolderivater, der bærer en amidfunktion, samt deres fremstilling og farmaceutiske sammensætninger indeholdende sådanne - Google Patents

Indolderivater, der bærer en amidfunktion, samt deres fremstilling og farmaceutiske sammensætninger indeholdende sådanne

Info

Publication number
DK0526348T3
DK0526348T3 DK92402213T DK92402213T DK0526348T3 DK 0526348 T3 DK0526348 T3 DK 0526348T3 DK 92402213 T DK92402213 T DK 92402213T DK 92402213 T DK92402213 T DK 92402213T DK 0526348 T3 DK0526348 T3 DK 0526348T3
Authority
DK
Denmark
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
DK92402213T
Other languages
English (en)
Inventor
Jean Wagnon
Claudine Serradeil-Legal
Bernard Tonnerre
Claude Plouzane
Dino Nisato
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0526348T3 publication Critical patent/DK0526348T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DK92402213T 1991-08-02 1992-08-03 Indolderivater, der bærer en amidfunktion, samt deres fremstilling og farmaceutiske sammensætninger indeholdende sådanne DK0526348T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
DK0526348T3 true DK0526348T3 (da) 1998-11-23

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92402213T DK0526348T3 (da) 1991-08-02 1992-08-03 Indolderivater, der bærer en amidfunktion, samt deres fremstilling og farmaceutiske sammensætninger indeholdende sådanne

Country Status (29)

Country Link
EP (1) EP0526348B1 (da)
JP (1) JP2633085B2 (da)
KR (1) KR100241583B1 (da)
AT (1) ATE163289T1 (da)
AU (2) AU658664B2 (da)
BR (1) BR9205336A (da)
CA (2) CA2093221C (da)
CZ (1) CZ288173B6 (da)
DE (1) DE69224450T2 (da)
DK (1) DK0526348T3 (da)
ES (1) ES2117038T3 (da)
FI (2) FI104069B (da)
FR (1) FR2679903B1 (da)
HK (1) HK1008741A1 (da)
HU (2) HUT68927A (da)
IL (3) IL102703A (da)
LT (1) LT3064B (da)
LV (1) LV10091B (da)
MX (1) MX9204487A (da)
MY (1) MY110517A (da)
NO (1) NO180047C (da)
NZ (1) NZ243795A (da)
PH (1) PH30661A (da)
RU (1) RU2104268C1 (da)
SG (1) SG47501A1 (da)
SK (1) SK283463B6 (da)
UA (1) UA27238C2 (da)
WO (1) WO1993003013A1 (da)
ZA (1) ZA925781B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811569A (pt) * 1997-07-31 2000-09-19 Elan Pharm Inc Compostos que inibem a adesão de leucócito mediada por vla-4
PL338373A1 (en) * 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811594A (pt) * 1997-07-31 2000-09-05 Elan Pharm Inc Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
CA2359115C (en) 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
AR035476A1 (es) 1999-01-22 2004-06-02 Elan Pharm Inc Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) * 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
AU1401902A (en) 2000-10-17 2002-04-29 Applied Research Systems Pharmaceutically active sulfanilide derivatives
WO2002044179A1 (fr) 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de 1,4,5,6-tétrahydroimidazo[4,5-d]diazépine ou sels de ces derniers
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
DK1458381T3 (da) 2001-12-20 2006-03-20 Applied Research Systems Triazoler som oxytocinantagonister
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2498091C (en) * 2002-10-11 2011-03-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
DK1940826T3 (da) 2005-09-29 2011-04-18 Elan Pharm Inc Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP5135235B2 (ja) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物
WO2010126914A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
IL102703A0 (en) 1993-01-14
KR100241583B1 (ko) 2000-03-02
UA27238C2 (uk) 2000-08-15
CA2093221A1 (en) 1993-02-03
FI980175A0 (fi) 1998-01-27
MY110517A (en) 1998-07-31
NO180047B (no) 1996-10-28
LV10091B (en) 1995-04-20
EP0526348A1 (fr) 1993-02-03
DE69224450D1 (de) 1998-03-26
CA2206776C (en) 2002-02-26
DE69224450T2 (de) 1998-07-30
NZ243795A (en) 1995-04-27
FI931476A0 (fi) 1993-04-01
IL117592A (en) 1999-04-11
JP2633085B2 (ja) 1997-07-23
NO180047C (no) 1997-02-05
IL102703A (en) 1997-03-18
AU2475892A (en) 1993-03-02
FI104069B1 (fi) 1999-11-15
CA2093221C (en) 1998-09-22
FI104069B (fi) 1999-11-15
PH30661A (en) 1997-09-16
MX9204487A (es) 1993-02-01
HU211884A9 (en) 1995-12-28
ES2117038T3 (es) 1998-08-01
FI107048B (fi) 2001-05-31
SK283463B6 (sk) 2003-08-05
SK42693A3 (en) 1993-10-06
IL117592A0 (en) 1996-07-23
CZ68293A3 (en) 1994-01-19
WO1993003013A1 (fr) 1993-02-18
FR2679903A1 (fr) 1993-02-05
HK1008741A1 (en) 1999-05-14
LV10091A (lv) 1994-05-10
CA2206776A1 (en) 1993-02-03
HUT68927A (en) 1995-08-28
RU2104268C1 (ru) 1998-02-10
LT3064B (en) 1994-10-25
FR2679903B1 (fr) 1993-12-03
NO931262D0 (no) 1993-04-01
NO931262L (no) 1993-05-26
CZ288173B6 (en) 2001-05-16
AU658664B2 (en) 1995-04-27
HU9300951D0 (en) 1993-06-28
JPH06501960A (ja) 1994-03-03
ATE163289T1 (de) 1998-03-15
FI980175A (fi) 1998-01-27
BR9205336A (pt) 1993-11-16
LTIP114A (en) 1994-06-15
FI931476A (fi) 1993-04-01
EP0526348B1 (fr) 1998-02-18
ZA925781B (en) 1993-03-02
AU691223B2 (en) 1998-05-14
SG47501A1 (en) 1998-04-17
AU1154195A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
DK0526348T3 (da) Indolderivater, der bærer en amidfunktion, samt deres fremstilling og farmaceutiske sammensætninger indeholdende sådanne
DK0454511T3 (da) N-substituerede heterocykliske derivater, deres fremstilling og farmaceutiske præparater indeholdende dem
HUP0500173A2 (hu) Alfa-szulfonamido-acetamid-származékok mint béta-amiloid inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
ES2002012A6 (es) Procedimiento para preparar (1,2,4)triazol (1,5-c)pirimidinas e-fusionadas
ES8205808A1 (es) Un procedimiento para la preparacion de nuevos derivados del acido 2-penem-3-carboxilico.
TW197420B (da)
ES8101045A1 (es) Procedimiento para la preparacion de derivados de acidos pi-rrolidinilsulfamoilbenzoicos sustituidos
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
FR2191887A1 (en) 7-Substd 5-hydroxy-imidazo pyrimidines - antiinflammatories, and immuno-suppressives, from 2-aminoimidazoline and substd ethyl acetates
ES8404362A1 (es) Un procedimiento para preparar nuevos compuestos de cefem.
HUP9903768A2 (hu) Vérképző sejtek proliferációját gátló peptidek